Table 1.

Antiproliferative activity of compounds 5a–k, 6a–c, 7, and Doxorubicin.

Compd.	Cell Viability %	Antiproliferative Activity IC50 ± SEM (µM)
		A-549	MCF-7	Panc-1	HT-29	Average
5a	89	3.70 ± 0.30	3.20 ± 0.30	3.90 ± 0.30	3.90 ± 0.30	3.70
5b	87	3.20 ± 0.30	2.90 ± 0.30	3.50 ± 0.30	3.60 ± 0.30	3.30
5c	87	1.70 ± 0.20	1.40 ± 0.20	1.80 ± 0.20	1.80 ± 0.20	1.70
5d	89	1.05 ± 0.10	0.90 ± 0.10	1.10 ± 0.10	1.10 ± 0.10	1.05
5e	93	0.95 ± 0.05	0.80 ± 0.05	1.00 ± 0.20	1.10 ± 0.10	0.95
5f	90	1.90 ± 0.20	1.70 ± 0.20	2.10 ± 0.20	2.10 ± 0.20	1.95
5g	89	4.90 ± 0.50	4.80 ± 0.50	5.20 ± 0.50	5.10 ± 0.50	5.00
5h	87	1.00 ± 0.10	0.90 ± 0.10	1.20 ± 0.10	1.20 ± 0.10	1.10
5i	90	1.55 ± 0.20	1.30 ± 0.10	1.60 ± 0.20	1.65 ± 0.20	1.50
5j	83	1.20 ± 0.10	1.00 ± 0.10	1.30 ± 0.10	1.30 ± 0.10	1.20
5k	87	1.40 ± 0.20	1.20 ± 0.10	1.50 ± 0.20	1.50 ± 0.20	1.40
6a	90	2.90 ± 0.30	2.60 ± 0.20	2.80 ± 0.20	2.90 ± 0.20	2.80
6b	91	2.50 ± 0.20	2.30 ± 0.20	2.65 ± 0.20	2.80 ± 0.20	2.60
6c	89	2.20 ± 0.20	2.10 ± 0.20	2.40 ± 0.20	2.50 ± 0.20	2.30
7	91	4.10 ± 0.40	4.00 ± 0.40	4.40 ± 0.40	4.60 ± 0.40	4.30
Doxorubicin	-	1.20 ± 0.20	0.90 ± 0.10	1.40 ± 0.20	1.00 ± 0.10	1.10